Mechanism Unearthed for Carfilzomib-Induced Reticulocytosis in Myeloma
Irreversible proteasome inhibitor carfilzomib appears to cause reticulocytosis in multiple myeloma by inhibiting terminal erythroid maturation.
Multiple Myeloma News
MULTIPLE MYELOMA ADVISOR
Multiple Myeloma News
Nelfinavir Plus Lenalidomide, Dexamethasone Improves Response in Lenalidomide-Refractory Multiple Myeloma
Results of a phase 1/2 trial demonstrated the efficacy of nelfinavir in combination with lenalidomide and dexamethasone for lenalidomide-refractory MM.
Real-World Insight on Patients With Multiple Myeloma: Results Drawn From a Large Health Plan
A retrospective cohort study identified real-world epidemiology, treatment patterns, and survival outcomes in patients with multiple myeloma in Israel.
Salvage Therapy Does Not Up Survival for Progressive Myeloma
Deepening of response through salvage therapy not linked to improved progression-free, overall survival.
A Simple Frailty Score Helped Predict Outcomes in Multiple Myeloma
The scoring system could be incorporated into future trials in elderly patients, authors said.
Suboptimal Implementation of Supportive Care in Older Patients With Multiple Myeloma
Factors associated with poor adherence to specific guideline-recommended supportive care measures involved patient race and site of care.
Selinexor-Dexamethasone Induced Responses in Triple-Refractory Myeloma
Responses were seen in patients who have few remaining treatment options.
Androgen Therapy in Lower-Risk Myelodysplastic Syndrome Can Result in Hematologic Improvement
Patients who received androgen therapy demonstrated improvements in erythroid, platelet, and neutrophil measures.
Patient Preferences Explored in Multiple Myeloma Treatment
An Eastern Cooperative Oncology Group (ECOG) performance status of ≥2 is linked to lower treatment satisfaction in patients with relapsed or refractory multiple myeloma (RRMM), but receiving medication orally is linked to higher satisfaction.
Tumor-Initiating Cell Marker Identified in Myeloma
A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
New Treatment Option Approved for Patients With Myelofibrosis
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Cost Burden of Disease Progression High in Multiple Myeloma
For patients receiving drug therapy, economic burden substantial across lines of therapy.
Measuring Low-Density Antigen Expression in Myeloma Cells Could Identify More Candidates for CAR-T Therapy
The antigen expression level on tumors that is necessary to engage and activate CAR-T cells is not currently known.
Unacceptable Benefit-to-Risk Ratio for Addition of Pembrolizumab to 2 Standard-of-Care Regimens in Multiple Myeloma
Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
SAVED Tool Improves Assessment of Venous Thromboembolism Risk in Patients With Multiple Myeloma
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
Oprozomib Found Active in Multiple Myeloma, Waldenström Macroglobulinemia
More work is needed to improve drug formulations for treatments for Waldenström macroglobulinemia.
Quantifying Driver Alterations in BCR-ABL1-Negative Myeloproliferative Neoplasms
A systematic review of studies sought to determine the likelihood of myeloproliferative neoplasm subtypes based on patients’ genetic alterations.
Switching to VTD During Chemotherapy Found to Be Linked to Better Outcomes in Older Patients
Elderly patients with myeloma who switched to bortezomib, thalidomide, and dexamethasone during frontline chemotherapy had better survival outcomes.
Analysis of Real-World Patients With Myeloma Who Have Extramedullary Disease
A retrospective analysis of myeloma patients with extramedullary disease provided insights into the characteristics that may influence outcomes.
Depressive Symptoms May Be Associated With Survival in Patients With Hematologic Malignancies
Patients with lymphoma or myeloma were assessed prior to and 1 month after initiating chemotherapy for depressive symptoms.
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma News
